Semax vs Selank
Which Is Right for You? Complete Comparison (2026)
Detailed comparison of Semax vs Selank. Learn the difference between these two Russian nootropic peptides — one stimulating, one calming.
Semax vs Selank: At a Glance
- ✓Synthetic ACTH(4-10) analogue — heptapeptide nootropic
- ✓Approved in Russia for stroke recovery and cognitive disorders
- ✓Enhances BDNF expression and neuroplasticity
- ✓Neuroprotective against oxidative stress and ischemia
- ✓Administered intranasally — crosses blood-brain barrier
- ✓Synthetic tuftsin analogue — heptapeptide anxiolytic
- ✓Approved in Russia for generalized anxiety and neurasthenia
- ✓Modulates GABA, serotonin, and dopamine systems
- ✓Immunomodulatory — enhances IL-6 and affects T-cell function
- ✓Administered intranasally — no sedation or dependence risk
Detailed Comparison
| Feature | Semax | Selank |
|---|---|---|
| Mechanism | Synthetic ACTH(4-10) analogue | Synthetic tuftsin analogueBest |
| Dosing | 200-600 mcg intranasally daily | 250-500 mcg intranasally daily |
| Administration | Intranasal | Intranasal |
| Half-life | ~30 seconds plasma; prolonged CNS activity | Minutes in plasma; prolonged CNS effects |
| FDA Status | Not FDA-approved (approved in Russia) | Not FDA-approved (approved in Russia) |
| Key Trial | Ashmarin IP et al. Neurosci Behav Physiol 2005 — cognitive enhancement | Zozulya AA et al. Bull Exp Biol Med 2001 — anxiolytic activity |
| Side Effects | Nasal irritation; generally well-tolerated | Nasal irritation; no significant adverse effects reported |
Which Should You Choose?
Semax (synthetic acth(4-10) analogue) and Selank (synthetic tuftsin analogue) serve different clinical roles despite both being in the Nootropic peptide space. Semax synthetic heptapeptide analogue of acth(4-10) with nootropic and neuroprotective properties. Selank synthetic heptapeptide analogue of tuftsin with anxiolytic and immunomodulatory properties.
Whichever you choose, track your protocol in Shotlee to build clean data for dose optimization and outcomes comparison.
Making an Informed Choice Between Semax and Selank
Choosing between Semax and Selank depends on multiple individual factors including your specific health goals, tolerance profile, insurance coverage, and prescriber recommendation. While clinical trial data provides population-level efficacy and safety comparisons, your personal response may differ based on genetics, baseline health, concurrent conditions, and lifestyle factors. Use this comparison as a starting framework and discuss the specifics with your healthcare provider.
Head-to-head clinical trial data between Semax and Selank is the gold standard for comparison, but such direct comparisons are not always available for every pair of compounds. Where head-to-head data is lacking, cross-trial comparisons provide useful but imperfect approximations — differences in patient populations, trial design, and endpoint definitions mean that numbers from separate trials are not directly interchangeable. Keep this context in mind when evaluating the comparison data presented here.
Tracking your personal response data in Shotlee is particularly valuable when switching between medications or considering a change. By documenting your outcomes on your current protocol — including efficacy metrics, side effect profile, adherence rate, and quality of life measures — you create an objective baseline for comparison if you transition to the alternative compound. This data transforms a subjective switching decision into an evidence-based protocol optimization.
Clinical Evidence Comparison: Semax vs Selank
Understanding the clinical evidence landscape for both Semax and Selank requires evaluating multiple dimensions beyond headline efficacy numbers. Important comparison axes include the quality and quantity of available clinical trial data, the specific patient populations studied, the duration of follow-up, the safety and tolerability profiles, the regulatory approval status and indicated uses, real-world accessibility and cost considerations, and the practicalities of administration and monitoring.
When evaluating clinical trial results, it is important to recognize that differences in trial design, patient demographics, concomitant therapies, and endpoint definitions can make direct numerical comparisons between separate trials misleading. Head-to-head randomized controlled trials provide the most reliable comparison data, but such studies are not available for all compound pairs. Where direct comparisons are absent, the available cross-trial data should be interpreted as hypothesis-generating rather than definitive.
Your individual response to Semax versus Selank may differ substantially from population averages reported in clinical trials. Factors including genetic polymorphisms, baseline metabolic health, concurrent medications, dietary patterns, physical activity levels, and stress or sleep quality all influence treatment response. Tracking your personal outcomes in Shotlee creates the individualized evidence base that population-level trial data cannot provide — and this personal data is ultimately what should drive your treatment decisions in consultation with your healthcare provider.
Semax vs Selank: Frequently Asked Questions
Semax is a synthetic acth(4-10) analogue while Selank is a synthetic tuftsin analogue. They differ in mechanism, dosing, and clinical evidence. Your choice should depend on your specific goals and medical history.
Switching should be done under medical supervision. Your prescriber can advise on transition protocols. Track both in Shotlee for comparison data.
Semax works as a synthetic acth(4-10) analogue (200-600 mcg intranasally daily), while Selank is a synthetic tuftsin analogue (250-500 mcg intranasally daily). They have different half-lives (~30 seconds plasma; prolonged CNS activity vs Minutes in plasma; prolonged CNS effects), side effect profiles, and levels of clinical evidence.
Yes. Shotlee supports tracking any medication or peptide. You can compare your results across different protocols.
Neither is universally better — the right choice depends on your individual health profile, treatment goals, side effect tolerance, insurance coverage, and prescriber recommendation. Clinical trial data shows efficacy differences in specific populations, but personal response varies. Track your experience with either medication in Shotlee to generate objective comparison data with your healthcare provider.
Switching between these medications should be done under medical supervision. Your prescriber will consider factors including your current response, reason for switching, dose equivalence, and transition timing. Use Shotlee to document your outcomes on the current medication so you have a clear baseline for comparison after switching.
Track Semax or Selank in Shotlee
Free dose tracking, side effect logging, and outcome comparison for any medication protocol.
📚References & sources
Latest on Semax
RFK Jr.'s Peptide Policy Could Boost Hims & Hers GLP-1 Shift
Shares of Hims & Hers surged after HHS Secretary RFK Jr. revealed FDA plans to review peptides for compounding under the 503A bulk list. This comes as the telehealth leader evolves its high-margin compounded GLP-1 business toward branded options and new peptide therapies. CEO Andrew Dudum and CMO Dr. Patrick Carroll highlight the potential for regulated, physician-led peptide access.
6 min read
Semax: Potential of a Synthetic Peptide in Neuroscience Research
Semax, a synthetic heptapeptide derived from ACTH research, is capturing interest for its neuroactive properties without endocrine effects. Ongoing studies highlight its roles in neuroplasticity, stress resilience, and cognitive function. This guide delves into the science behind its multifaceted research potential.
5 min read
Semax Peptide: Research on Neuroprotection, Inflammation, and Vascular Effects
Semax, a synthetic heptapeptide, has demonstrated neuroregulatory, neuroprotective, and immunomodulating properties in various research models. This article examines its biochemical characteristics, possible effects on gene expression, interactions with neurotransmitter systems, vascular modulation, metal binding, and utility in ischemia-reperfusion injury studies.
5 min read